Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Reduced Intensity Therapy for Primary Central Nervous System Post-Transplant Lymphoproliferative Disorders (PTLD) Is Associated with Preserved Survival Outcomes: A Twenty-Year Single-Institutional Experience

Bradley Shogo Uyemura, Zhanhai Li, David T Yang, Michael Fallon, Jon S Odorico, Julie E Chang

Blood (2024) 144 (Supplement 1): 6447.

https://doi.org/10.1182/blood-2024-193519

Published: 2024

Journal Articles

A Phase I/II Study of Tazemetostat Combined with Abbreviated Rituximab/Bendamustine Therapy for High Tumor Burden Follicular Lymphoma in Frontline Treatment: A Big Ten Cancer Research Consortium Study

Blood (2024) 144 (Supplement 1): 4415.

https://doi.org/10.1182/blood-2024-202639

Published: 2024

Journal Articles

Minimal Residual Disease (MRD) Testing By Next Generation Sequencing (NGS) after Two Cycles (CY) of Non-Intensive Chemoimmunotherapy Is Predictive of Remission Duration and Need for Maintenance Therapy (MT) in Previously Untreated Mantle Cell Lymphoma (MCL): A Wisconsin Oncology Network Study

Danielle McQuinn, Meredith Hyun, KyungMann Kim, Vaishalee P Kenkre, Christopher D Fletcher, Saurabh A Rajguru, Priyanka A Pophali, Mariah Endres, Mitch Howard, Tim Wassenaar, Ruth Callaway Warren, Ryan J Mattison, Kari B Wisinski, Julie E Chang

Blood (2023) 142 (Supplement 1): 4407.

https://doi.org/10.1182/blood-2023-173871

Published: 2023

Journal Articles

A Multicenter Real-World Analysis (RWA) of Primary Cutaneous Anaplastic Large Cell Lymphoma (PCALCL) Treated in the Modern Era

Deepa Jagadeesh, Stefan K. Barta, Jonathan E. Brammer, Wei Wei, Julie E Chang, Rahul Mishra, Tavakkoli Montreh, Alma Habib, Marcus P Watkins, Yash Deshmukh, Sharina C Macapagal, Madiha Iqbal, N. Nora Bennani, Frederick Lansigan, Neha Mehta-Shah

Blood (2023) 142 (Supplement 1): 6177.

https://doi.org/10.1182/blood-2023-191176

Published: 2023

Journal Articles

High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series

Blood (2022) 140 (Supplement 1): 3839–3841.

https://doi.org/10.1182/blood-2022-157105

Published: 2022

Journal Articles

A Multi-Center Retrospective Review of COVID-19 Outcomes in Patients with Lymphoid Malignancy

Blood (2021) 138 (Supplement 1): 184.

https://doi.org/10.1182/blood-2021-146398

Published: 2021

Journal Articles

Outcomes of Primary Bone Diffuse Large B-Cell Lymphoma in the Rituximab Era: A Multicenter Retrospective Analysis

Blood (2021) 138 (Supplement 1): 1451.

https://doi.org/10.1182/blood-2021-145145

Published: 2021

Journal Articles

Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study

Giselle K. Perez, PhD, Fangxin Hong, PhD, Andrew M. Evens, DO,MMSc, Thomas M. Habermann, MD, Ranjana Advani, MD, Stephen M. Ansell, MD PhD, Puneet S. Cheema, MD, Philip A. Dy, MD, Timothy E. O'Brien, MD, Jane N. Winter, MD, Julie E. Chang, MD, David Cella, PhD, Brad S. Kahl, MD, Lynne I. Wagner, PhD

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-140502

Published: 2020

Journal Articles

Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Naïve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven)

Jennifer R. Brown, MD PhD, Matthew S. Davids, MD, Julie E Chang, MD, Shuo Ma, MD PhD, Juliana M L Biondo, MD, Yong Mun, PhD, Madlaina Breuleux, PhD, William G. Wierda, MD PhD

Blood (2019) 134 (Supplement_1): 4320.

https://doi.org/10.1182/blood-2019-123665

Published: 2019

Journal Articles

Lenalidomide and Rituximab Maintenance Therapy after Front-Line Induction Chemoimmunotherapy in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Julie E Chang, MD, Vaishalee P. Kenkre, MD, Christopher D. Fletcher, MD, Aric C. Hall, MD, Natalie Scott Callander, MD, Kyungmann Kim, PhD, Grace Yi Chen, Kaitlin Chambers

Blood (2019) 134 (Supplement_1): 5470.

https://doi.org/10.1182/blood-2019-124489

Published: 2019

Journal Articles

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET

David J. Straus, Sin-Ho Jung, Brandelyn Pitcher, Lale Kostakoglu, John C. Grecula, Eric D. Hsi, Heiko Schöder, Leslie L. Popplewell, Julie E. Chang, Craig H. Moskowitz, Nina Wagner-Johnston, John P. Leonard, Jonathan W. Friedberg, Brad S. Kahl, Bruce D. Cheson, Nancy L. Bartlett

Blood (2018) 132 (10): 1013–1021.

https://doi.org/10.1182/blood-2018-01-827246

Published: 2018

Includes: Supplemental data

Journal Articles

Durable Remissions with the VcR-CVAD Regimen for Mantle Cell Lymphoma (MCL), Regardless of Age: Long-Term Follow-up of a Wisconsin Oncology Network (WON) Study

Julie E. Chang, MD, Christopher Peterson, MD, Lakeesha L. Carmichael, MS, KyungMann Kim, PhD, David T. Yang, MD, Anne M. Traynor, MD, Jae E. Werndli, BSc, MSc, Michael Huie, MD, Thomas McFarland, MD, Michael Volk, MD, Jules H. Blank, MD, Natalie S. Callander, MD, Walter L. Longo, MD, Brad S. Kahl, MD

Blood (2016) 128 (22): 149.

https://doi.org/10.1182/blood.V128.22.149.149

Published: 2016

Journal Articles

Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303

Blood (2016) 128 (22): 469.

https://doi.org/10.1182/blood.V128.22.469.469

Published: 2016

Journal Articles

Initial Results of US Intergroup Trial of Response-Adapted Chemotherapy or Chemotherapy/Radiation Therapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604)

David J. Straus, MD, Brandelyn Pitcher, MS, Lale Kostakoglu, MD MPH, John C Grecula, MD, Eric D. Hsi, MD, Heiko Schoder, MD, Sin-Ho Jung, PhD, Leslie L. Popplewell, MD, Julie E Chang, MD, Craig H Moskowitz, MD, Nina Wagner-Johnson, MD, John P. Leonard, MD, Jonathan W. Friedberg, MD MMSc, Brad S Kahl, MD, Bruce D. Cheson, MD, Nancy L. Bartlett, MD

Blood (2015) 126 (23): 578.

https://doi.org/10.1182/blood.V126.23.578.578

Published: 2015

Journal Articles

Activating STAT6 mutations in follicular lymphoma

Mehmet Yildiz, Hongxiu Li, Denzil Bernard, Nisar A. Amin, Peter Ouillette, Siân Jones, Kamlai Saiya-Cork, Brian Parkin, Kathryn Jacobi, Kerby Shedden, Shaomeng Wang, Alfred E. Chang, Mark S. Kaminski, Sami N. Malek

Blood (2015) 125 (4): 668–679.

https://doi.org/10.1182/blood-2014-06-582650

Published: 2015

Includes: Supplemental data

Journal Articles

Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)

Julie E. Chang, Hailun Li, Mitchell R. Smith, Randy D. Gascoyne, Elisabeth M. Paietta, David T. Yang, Ranjana H. Advani, Sandra J. Horning, Brad S. Kahl

Blood (2014) 123 (11): 1665–1673.

https://doi.org/10.1182/blood-2013-08-523845

Published: 2014

Includes: Supplemental data

Journal Articles

Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma

Hongxiu Li, Mark S. Kaminski, Yifeng Li, Mehmet Yildiz, Peter Ouillette, Siân Jones, Heather Fox, Kathryn Jacobi, Kamlai Saiya-Cork, Dale Bixby, Daniel Lebovic, Diane Roulston, Kerby Shedden, Michael Sabel, Lawrence Marentette, Vincent Cimmino, Alfred E. Chang, Sami N. Malek

Blood (2014) 123 (10): 1487–1498.

https://doi.org/10.1182/blood-2013-05-500264

Published: 2014

Includes: Supplemental data

Journal Articles

Final Results Of a Phase I Study Of The Anti-CD22 Antibody-Drug Conjugate (ADC) DCDT2980S With Or Without Rituximab (RTX) In Patients (Pts) With Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin’s Lymphoma (NHL)

Ranjana Advani, MD, Andy I. Chen, MD, PhD, Daniel Lebovic, MD, Mark W. Brunvand, MD, Andre Goy, MD, Julie E. Chang, MD, Ephraim Hochberg, Sreeni Yalamanchili, BSPharm, Robert Kahn, Dan Lu, Akiko Chai, MS, Yu-Waye Chu, Bruce D. Cheson, M.D.

Blood (2013) 122 (21): 4399.

https://doi.org/10.1182/blood.V122.21.4399.4399

Published: 2013

Journal Articles

Results of a Phase 1 Dose-Escalation Study of Once-Weekly MLN9708, an Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma

Sarit Assouline, Julie E. Chang, MD, Bruce D. Cheson, MD, Robert Rifkin, MD, Solomon Hamburg, MD, PhD, Ruben Reyes, MD, Ai-Min Hui, MD, PhD, Jiang Yu, Neeraj Gupta, PhD, Alessandra Di Bacco, PhD, Yaping Shou, Peter Martin, MD

Blood (2012) 120 (21): 3646.

https://doi.org/10.1182/blood.V120.21.3646.3646

Published: 2012

Journal Articles

Bendamustine + Rituximab (BR) Chemoimmunotherapy and Maintenance Lenalidomide in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Wisconsin Oncology Network (WON) Study

Blood (2012) 120 (21): 3647.

https://doi.org/10.1182/blood.V120.21.3647.3647

Published: 2012

NARROW

Reduced Intensity Therapy for Primary Central Nervous System Post-Transplant Lymphoproliferative Disorders (PTLD) Is Associated with Preserved Survival Outcomes: A Twenty-Year Single-Institutional Experience

A Phase I/II Study of Tazemetostat Combined with Abbreviated Rituximab/Bendamustine Therapy for High Tumor Burden Follicular Lymphoma in Frontline Treatment: A Big Ten Cancer Research Consortium Study

Minimal Residual Disease (MRD) Testing By Next Generation Sequencing (NGS) after Two Cycles (CY) of Non-Intensive Chemoimmunotherapy Is Predictive of Remission Duration and Need for Maintenance Therapy (MT) in Previously Untreated Mantle Cell Lymphoma (MCL): A Wisconsin Oncology Network Study

A Multicenter Real-World Analysis (RWA) of Primary Cutaneous Anaplastic Large Cell Lymphoma (PCALCL) Treated in the Modern Era

High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series

A Multi-Center Retrospective Review of COVID-19 Outcomes in Patients with Lymphoid Malignancy

Outcomes of Primary Bone Diffuse Large B-Cell Lymphoma in the Rituximab Era: A Multicenter Retrospective Analysis

Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study

Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Naïve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven)

Lenalidomide and Rituximab Maintenance Therapy after Front-Line Induction Chemoimmunotherapy in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET

Durable Remissions with the VcR-CVAD Regimen for Mantle Cell Lymphoma (MCL), Regardless of Age: Long-Term Follow-up of a Wisconsin Oncology Network (WON) Study

Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303

Initial Results of US Intergroup Trial of Response-Adapted Chemotherapy or Chemotherapy/Radiation Therapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604)

Activating STAT6 mutations in follicular lymphoma

Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)

Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma

Final Results Of a Phase I Study Of The Anti-CD22 Antibody-Drug Conjugate (ADC) DCDT2980S With Or Without Rituximab (RTX) In Patients (Pts) With Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin’s Lymphoma (NHL)

Results of a Phase 1 Dose-Escalation Study of Once-Weekly MLN9708, an Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma

Bendamustine + Rituximab (BR) Chemoimmunotherapy and Maintenance Lenalidomide in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Wisconsin Oncology Network (WON) Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only